Lucid Diagnostics Inc

LUCD remains in a clear Stage 4 downtrend with persistent lower-high/lower-low structure and price rejected at falling EMAs. The medium-term bias is bearish under distribution dynamics, and tactical timing favors selling on bounce attempts into resistance. On the short term, recent rallies into the 9/21 EMA have failed and RSI remains oversold, supporting an immediate sell posture. The primary risk is a shallow exhaustion-driven bounce that could trap sellers before continuation. Bearish bias would be invalidated by a sustained daily close back above the 21 EMA and the last lower high.

• ↑Pending Medicare coverage for eSAGARD could unlock 40–50% of the addressable market.
• ↑First VA purchase orders executed; Q1 saw 3,177 tests generating $1.3M revenue.
• ↓Earnings yield is deeply negative, pointing to poor equity returns.